MX2022013427A - Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. - Google Patents
Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer.Info
- Publication number
- MX2022013427A MX2022013427A MX2022013427A MX2022013427A MX2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A MX 2022013427 A MX2022013427 A MX 2022013427A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- methods
- subject
- agitation associated
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 238000013019 agitation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 abstract 1
- MKXZASYAUGDDCJ-QNNIAVNKSA-N deudextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C([2H])([2H])[2H])[C@H]2CC2=CC=C(OC([2H])([2H])[2H])C=C21 MKXZASYAUGDDCJ-QNNIAVNKSA-N 0.000 abstract 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 abstract 1
- 229960004482 quinidine sulfate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En algunas modalidades proporcionadas en la presente se encuentra un método para tratar la agitación asociada con la enfermedad de Alzheimer en un sujeto, que comprende administrarle al sujeto cantidades terapéuticamente eficaces de bromhidrato de [d6]-dextrometorfano deuterado (d6-DM) y sulfato de quinidina, donde el sujeto es un paciente al que se le ha diagnosticado la enfermedad de Alzheimer, donde el método comprende determinar la puntuación total del inventario de agitación de Cohen-Mansfield (CMAI) en el paciente antes de dicha administración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016270P | 2020-04-27 | 2020-04-27 | |
| PCT/US2021/029246 WO2021222145A1 (en) | 2020-04-27 | 2021-04-26 | Methomethods of treating agitation associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013427A true MX2022013427A (es) | 2023-01-19 |
Family
ID=75914613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013427A MX2022013427A (es) | 2020-04-27 | 2021-04-26 | Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230270738A1 (es) |
| EP (1) | EP4142729A1 (es) |
| JP (1) | JP2023523373A (es) |
| KR (1) | KR20230016636A (es) |
| CN (1) | CN115734787A (es) |
| AU (1) | AU2021263354A1 (es) |
| BR (1) | BR112022021535A2 (es) |
| CA (1) | CA3176234A1 (es) |
| IL (1) | IL296977A (es) |
| MX (1) | MX2022013427A (es) |
| TW (1) | TW202203922A (es) |
| WO (1) | WO2021222145A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| US20230131493A1 (en) * | 2021-10-27 | 2023-04-27 | Avanir Phrmaceuticals Inc. | Methods of treating agitation associated with alzheimer's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US20160143901A1 (en) * | 2006-02-03 | 2016-05-26 | Avanir Pharmaceuticals, Inc. | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia |
| MX2009011958A (es) | 2007-05-01 | 2010-06-30 | Concert Pharmaceuticals Inc | Compuestos de morfina. |
| EP3708168A3 (en) * | 2014-09-14 | 2020-12-09 | Avanir Pharmaceuticals, Inc. | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia |
-
2021
- 2021-04-26 CA CA3176234A patent/CA3176234A1/en active Pending
- 2021-04-26 JP JP2023509465A patent/JP2023523373A/ja active Pending
- 2021-04-26 CN CN202180045685.XA patent/CN115734787A/zh active Pending
- 2021-04-26 IL IL296977A patent/IL296977A/en unknown
- 2021-04-26 KR KR1020227041229A patent/KR20230016636A/ko active Search and Examination
- 2021-04-26 BR BR112022021535A patent/BR112022021535A2/pt unknown
- 2021-04-26 MX MX2022013427A patent/MX2022013427A/es unknown
- 2021-04-26 AU AU2021263354A patent/AU2021263354A1/en active Pending
- 2021-04-26 WO PCT/US2021/029246 patent/WO2021222145A1/en active Application Filing
- 2021-04-26 US US17/921,579 patent/US20230270738A1/en active Pending
- 2021-04-26 EP EP21725652.8A patent/EP4142729A1/en active Pending
- 2021-04-27 TW TW110115202A patent/TW202203922A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021222145A1 (en) | 2021-11-04 |
| CN115734787A (zh) | 2023-03-03 |
| EP4142729A1 (en) | 2023-03-08 |
| IL296977A (en) | 2022-12-01 |
| TW202203922A (zh) | 2022-02-01 |
| CA3176234A1 (en) | 2021-11-04 |
| JP2023523373A (ja) | 2023-06-02 |
| KR20230016636A (ko) | 2023-02-02 |
| WO2021222145A8 (en) | 2021-12-30 |
| BR112022021535A2 (pt) | 2023-01-24 |
| US20230270738A1 (en) | 2023-08-31 |
| AU2021263354A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013427A (es) | Metodos de tratamiento de la agitacion asociada a la enfermedad de alzheimer. | |
| Fu et al. | Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint | |
| MX2021000778A (es) | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. | |
| JAFFE et al. | Generalized scleroderma in children: acrosclerotic type | |
| MX2021011203A (es) | Metodos para tratar sintomas negativos de esquizofrenia usando dextrometorfan deuterado y quinidina. | |
| Lierz et al. | Comparison between bupivacaine 0.125% and ropivacaine 0.2% for epidural administration to outpatients with chronic low back pain | |
| FREYDBERG | The place of corticotropin in the treatment of myasthenia gravis | |
| Anwar et al. | Combined botulinum toxin injections and phenol nerve/motor point blocks to manage multifocal spasticity in adults | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| Li et al. | Therapeutic observation of Fu’s subcutaneous needling for scapulohumeral periarthritis | |
| Š? ÁVA et al. | Salazopyrin in the treatment of scleroderma | |
| SUN et al. | Observation on the effect difference in migraine treated with the combination of acupuncture and blood-letting therapy and medication with carbamazepine | |
| Ma et al. | Summary on clinical experience of acupuncture treating dry eye syndromes | |
| RU2810400C1 (ru) | Способ лечения стероидной розацеа по точкам | |
| Shen et al. | Effect of acupuncture and tuina plus rehabilitative therapy on lower limb motor dysfunction in infants with spastic cerebral palsy | |
| Wang et al. | Therapeutic efficacy observation on combining interaction and routine acupuncture for intractable facial palsy | |
| Lamei et al. | Exploring the Acupuncture Point Pattern of Acupuncture for Diabetic Retinopathy Based on Data Mining | |
| Grimsom | Consideration of Actions and Uses of a Few of the Drugs Which Suppress or Interrupt Sympathetic Nerve Transmission | |
| Zwölfer et al. | Acupuncture in Gonarthrotic Pain—" Bachmann's Knee Program" | |
| Davis | Case of Raynaud's disease associated with calcareous degeneration | |
| McDermott | Streptomycin in the treatment of tuberculosis | |
| Zhang et al. | Introduction to quick and surround needling method for nodular goiter | |
| Smith | NEW ENGLAND DERMATOLOGICAL SOCIETY | |
| Wilder | Long range treatment of multiple sclerosis with pancorphen | |
| Bell et al. | Properties of PME. |